Blocking the B-cell receptor (BCR) with ibrutinib and other BTKi drugs has revolutionized care in CLL. PI3K inhibitors also block that same receptor and are remarkably effective in treating CLL. Join Dr. Ian Flinn who will explain how these treatments work, the common side effects, and what role they
March 27, 2023
BREAKING NEWS
Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Menu
